Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Lexicon Pharmaceuticals revenue
Lexicon Pharmaceuticals's revenue is $31.1 million.
What is Lexicon Pharmaceuticals's revenue?
- Lexicon Pharmaceuticals's revenue growth from 2005 to 2024 is -58.93%.
- Lexicon Pharmaceuticals has 225 employees, and the revenue per employee ratio is $138,137.
- Lexicon Pharmaceuticals's peak quarterly revenue was $294.4M in 2019(q3).
- Lexicon Pharmaceuticals peak revenue was $322.1M in 2019.
- Lexicon Pharmaceuticals annual revenue for 2023 was 1.2M, 766.19% growth from 2022.
- Lexicon Pharmaceuticals annual revenue for 2024 was 31.1M, 2,481.48% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Lexicon Pharmaceuticals historical revenue
Lexicon Pharmaceuticals's peak revenue was $322.1M in 2019. The peak quarterly revenue was $294.4M in 2019(q3).
Lexicon Pharmaceuticals's revenue increased from $75.7m in 2005 to $31.1M currently. That's a -58.93% change in annual revenue.
Lexicon Pharmaceuticals annual revenue
Lexicon Pharmaceuticals annual revenue over time
| Fiscal year / year | Lexicon Pharmaceuticals revenue |
|---|---|
| 2009 | $10.7M |
| 2010 | $4.9M |
| 2011 | $1.8M |
| 2012 | $1.1M |
| 2013 | $2.2M |
| 2014 | $22.9M |
| 2015 | $130.0M |
| 2016 | $79.3M |
| 2017 | $91.7M |
| 2018 | $63.2M |
| 2019 | $322.1M |
| 2020 | $24.0M |
| 2021 | $298,000 |
| 2022 | $139,000 |
| 2023 | $1.2M |
| 2024 | $31.1M |
Rate Lexicon Pharmaceuticals' financial transparency
Lexicon Pharmaceuticals annual growth
Lexicon Pharmaceuticals saw the greatest revenue growth in 2014, when revenue increased by 928.53%.
Lexicon Pharmaceuticals had the lowest revenue growth in 2021, when revenue changed by -98.76%.
Lexicon Pharmaceuticals annual growth rate over time
| Year | Lexicon Pharmaceuticals growth |
|---|---|
| 2009 | -67%↓ |
| 2010 | -54%↓ |
| 2011 | -62%↓ |
| 2012 | -41%↓ |
| 2013 | 104%↑ |
| 2014 | 929%↑ |
| 2015 | 469%↑ |
| 2016 | -39%↓ |
| 2017 | 16%↑ |
| 2018 | -31%↓ |
| 2019 | 410%↑ |
| 2020 | -93%↓ |
| 2021 | -99%↓ |
| 2022 | -53%↓ |
| 2023 | 766%↑ |
| 2024 | 2481%↑ |
Lexicon Pharmaceuticals quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Lexicon Pharmaceuticals quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2009 | $4.2M | $3.0M | $2.1M | $1.4M |
| 2010 | $1.6M | $1.2M | $781,000 | $1.3M |
| 2011 | $596,000 | $555,000 | $355,000 | $343,000 |
| 2012 | $300,000 | $199,000 | $372,000 | $218,000 |
| 2013 | $360,000 | $214,000 | $238,000 | $1.4M |
| 2014 | $277,000 | $676,000 | $419,000 | $21.5M |
| 2015 | $1.8M | $376,000 | $566,000 | $127.3M |
| 2016 | $12.5M | $20.1M | $27.7M | $19.0M |
| 2017 | $18.3M | $12.1M | $26.9M | $34.4M |
| 2018 | $25.2M | $13.8M | $6.9M | $17.4M |
| 2019 | $9.2M | $9.7M | $294.4M | $8.7M |
| 2020 | $8.0M | $9.2M | $6.6M | $199,000 |
| 2021 | $27,000 | $234,000 | $23,000 | $14,000 |
| 2022 | $37,000 | $35,000 | $39,000 | $28,000 |
| 2023 | $24,000 | $317,000 | $162,000 | $702,000 |
| 2024 | $1.1M | $1.6M | $1.8M | $26.6M |
Lexicon Pharmaceuticals jobs nearby
Do you work at Lexicon Pharmaceuticals?
Did Lexicon Pharmaceuticals meet its revenue projections?
Lexicon Pharmaceuticals financial information
| CEO | Lonnel Coats |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 225 |
| Date Founded | 1995 |
| Headquarters | The Woodlands, Texas |
| Number of Locations | 24 |
| Revenue | $31.1M |
| Net Income | -$101,944,000 |
| Gross Proft | $30.5M (2024) |
| PE Ratio | -2.83 |
| Tax Rate | 0.0% |
| Market Capitalization | $566.7M |
| Total Assets | $194,299,000 |
| Ticker | LXRX |
Lexicon Pharmaceuticals jobs you might like
Lexicon Pharmaceuticals financing
Lexicon Pharmaceuticals received early financing of $31.8M on 1999-01-01.
| Series | Round size | Date |
|---|---|---|
| Post Ipo Equity | $31.8M | 01/1999 |
| Grant | $2M | 05/2006 |
| Post Ipo Equity | $75M | 03/2010 |
| Post Ipo Equity | $35M | 08/2012 |
| Post Ipo Equity | $4.7M | 12/2014 |
| Post Ipo Debt | $150M | 12/2017 |
| Post Ipo Debt | $150M | 03/2022 |
Lexicon Pharmaceuticals investors
| Investors | Security type |
|---|---|
| The Walden Group | Post Ipo Equity |
| BCM Technologies Inc | Post Ipo Equity |
| Bay City Capital | Post Ipo Equity |
| Sofinov Societe Financiere D Innovation | Post Ipo Equity |
| SR One | Post Ipo Equity |
| Punk Ziegel & Company | Post Ipo Equity |
| GeneChem Management Inc. | Post Ipo Equity |
| Patricof & Co. Ventures | Post Ipo Equity |
| USAMRMC | Grant |
| U.S. Army Medical Research & Development Command | Grant |
| Invus | Post Ipo Equity |
| Oxford Finance LLC | Post Ipo Debt |
Lexicon Pharmaceuticals competitors
Lexicon Pharmaceuticals's top competitor, Alnylam Pharmaceuticals, earned an annual revenue of $2.2B.
Lexicon Pharmaceuticals's smallest competitor is Emisphere Technologies with revenue of $1.2M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| PTC Therapeutics | $92,986 | $806.8M | 517 | 12 |
| Merrimack Pharmaceuticals | $90,170 | $102.8M | 426 | - |
| Momenta Pharmaceuticals | $76,894 | $30.1M | 131 | - |
| Alnylam Pharmaceuticals | $81,014 | $2.2B | 1,323 | 1 |
| Aradigm | $68,338 | $14.5M | 23 | - |
| Yumanity Therapeutics | $96,863 | $1.9B | 23,876 | - |
| Portola Pharmaceuticals | $83,155 | $116.6M | 324 | - |
| AMRI | $76,714 | $276.6M | 3,085 | - |
| AVEO Oncology | $74,270 | $42.3M | 20 | 13 |
| Emisphere Technologies | $71,999 | $1.2M | 76 | - |
Lexicon Pharmaceuticals revenue FAQs
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Lexicon Pharmaceuticals highest paying jobs
Zippia gives an in-depth look into the details of Lexicon Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Lexicon Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Lexicon Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Lexicon Pharmaceuticals. The data presented on this page does not represent the view of Lexicon Pharmaceuticals and its employees or that of Zippia.
Lexicon Pharmaceuticals may also be known as or be related to LEXICON PHARMACEUTICALS INC., LEXICON PHARMACEUTICALS, INC., Lexicon Pharmaceuticals, Lexicon Pharmaceuticals Inc, Lexicon Pharmaceuticals, Inc and Lexicon Pharmaceuticals, Inc.